Kynurenine pathway (KP) inhibitors: Novel agents for the management of depression

Journal of Psychopharmacology

Volumn 29, Issue 10, 2015, Pages 1133-1134

  Hazari, Nandita ^a   Bhad, Roshan ^b  

^a KEM HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

depression; Kynurenine pathway; novel drugs; psychopharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; KYNURENINE; KYNURENINE PATHWAY INHIBITOR; LAQUINIMOD; LEFLUNOMIDE; UNCLASSIFIED DRUG;

ARTICLE; COMORBIDITY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; GENETIC RISK; HUMAN; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REACTIVE DEPRESSION; SECONDARY DEPRESSION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; KYNURENINE; SIGNAL TRANSDUCTION;

EID: 84942119943     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115599386     Document Type: Article

References (10)

1. Copolov DL, Rubin RT, Mander AJ, et al. (1986) DSM-III melancholia: Do the criteria accurately and reliably distinguish endogenous pattern depression? J Affect Disord 10: 191-202.
2. Fukuda K, (2014) Etiological classification of depression based on the enzymes of tryptophan metabolism. BMC Psychiatry 14: 8.
3. Köhler O, Benros ME, Nordentoft M, et al. (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71: 1381-1391.
4. Miller C, (2011) The kynurenine pathway: Modeling the interaction between genes and nutrition in schizophrenia. J Orthomolecular Med 26: 59-84.
5. Nagineni CN, Pardhasaradhi K, Martins MC, et al. (1996) Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun 64: 4188-4196.
6. Oxenkrug G, (2013) Serotonin-kynurenine hypothesis of depression: Historical overview and recent developments. Curr Drug Targets 14: 514-521.
7. Savitz J, Drevets WC, Smith CM, et al. (2015) Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 40: 463-471.
8. Stone TW, Forrest CM, Darlington LG, (2012) Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J 279: 1386-1397.
9. Vécsei L, Szalárdy L, Fülöp F, et al. (2013) Kynurenines in the CNS: Recent advances and new questions. Nat Rev Drug Discov 12: 64-82.
10. Whiteford HA, Degenhardt L, Rehm J, et al. (2013) Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet 382: 1575-1586.